

Reference	Research Project Title	IRB	Name of Conflicted	Business Entity	Nature of Financial Interest	Approximate Dollar Value
ICI_00000146	A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor	IRB_00092217	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00000458	Janssen 56021927PCR3002 TITAN>>A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormonesensitive Prostate Cancer (mHSPC)	IRB_00093728	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00000473	Novartis CABL001X2101>>A Phase I, Multicenter, Open-Label Study Of Oral ABL001 In Patients With Chronic Myelogenous Leukemia Or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	IRB_00094141	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00001139	Janssen 54767414MMY2004>>Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation	IRB_00098018	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00001261	Cantex Pharmaceuticals CAN-201>> A Phase II, Multicenter, Open-Label, Single Arm Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma	IRB_00098312	the University of Utah	the University of Utah	intellectual property	The University of Utah owns the patent to the technology (disulfiram and copper gluconate) being evaluated in the study. The value of the intellectual property cannot be readily determined.
ICI_00001761	PCCTC c16-168: BRCAAway >>A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects	IRB_00101708	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00001930	Alliance A051301 (CIRB)>>A Randomized Double-Blind Phase III Study of Ibrutinib during and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype	IRB_00102756	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00002154	Janssen 54767414AMY3001>>A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared with CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis.	IRB_00102833	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00002794	Cancer Risk and Prevention in Lynch Syndrome	IRB_00106878	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00002994	T2016-001, A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin's Lymphoma (Protocol 54179060LYM3003; Sparkle)	IRB_00108757	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00003050	Psychophysical perceptions evoked by electrical currents injected via an array of microelectrodes implanted in human visual cortex	IRB_00104283	the University of Utah Dr. Florian Solzbacher, Department Chair of Electrical and Computer Engineering	Blackrock Microsystems	intellectual property equity	The University of Utah owns the intellectual property being used and evaluated in this study – the Utah Electrode Array (UEA). The UEA is licensed to Blackrock Microsystems, LLC., a start up company in which the University holds an equity interest. Dr. Florian Solzbacher, Department Chair of Electrical and Computer Engineering, is a co-founder of Blackrock. Dr. Solzbacher is an inventor of the intellectual property licensed by Blackrock. The value of the intellectual property cannot be readily determined.

Reference	Research Project Title	IRB	Name of Conflicted	Business Entity	Nature of Financial Interest	Approximate Dollar Value
ICI_00004400	ACADEMIC: A Randomized Phase II Clinical Trial of ADT Combined with Abiraterone or Docetaxel in Metastatic Hormone Sensitive Prostate Cancer	IRB_00115099	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00004474	Celgene BB2121-MM-003>>A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (KarMMA-3)	IRB_00116779	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00004501	Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement Continued Access Trial (to IRB 91735)	IRB_00116371	Dr. Frederick Welt, Vice Chair of Clinical Affairs in the Department of Internal Medicine	Medtronic	remuneration	\$10,000-19,000
ICI_00005478	Alliance A041702 (NCI CIRB) >> A Randomized Phase iii Study Of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax And Obinutuzumab In Untreated Older Patients (≥ 70 Years Of Age) With Chronic Lymphocytic Leukemia (CLL)	IRB_00120440	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00006264	Merck MK-7339-010 >> A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)	IRB_00121989	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00006604	Janssen 54767414MMY3021>>A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant	IRB_00123033	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00006864	The BREASTrial: Breast Reconstruction Evaluation using Acellular dermal matrix as a Sling Trial	IRB_00026658	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00006919	OSU-14087 >> A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma	IRB_00085518	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00007304	DFCI-HCC 16-383>> A Phase 2 Study of Abemaciclib in Recurrent Glioblastoma	IRB_00098307	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00007337	Ivabradine for Treatment of Tachyarrhythmias in Pediatric and Congenital Heart Disease Patients: A Multicenter Registry	IRB_00124849	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00007341	Inflammatory Response Following Intraarticular Fracture	IRB_00051134	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00007391	Northwestern University NU-14H06>>A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients with Previously Untreated Mantle Cell Lymphoma (MCL)	IRB_00087891	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00007399	I4V-MC-JAIX - A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis	IRB_00108901	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00007400	Protocol 11F-MC-RHBC, A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension	IRB_00058072	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00007426	PCYC-1146-IM Ibrutinib: Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)	IRB_00120053	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000

Reference	Research Project Title	IRB	Name of Conflicted	Business Entity	Nature of Financial Interest	Approximate Dollar Value
ICI_00007611	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)	IRB_00103398	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00007652	BMS CA209-722>>Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy	IRB_00095965	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00007657	Janssen 63898081EDI1001>>A Phase 1, First-in-Human, Dose Escalation Study of JNJ- 63898081 in Subjects with Advanced Stage Solid Tumors	IRB_00125261	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00007667	Alliance A071701 (NCI CIRB) >> Genomically-Guided Treatment Trial in Brain Metastases	IRB_00125753	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00007686	I4V-MC-JAHO - A Multicenter, Randomized Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata - BRAVE-AA1	IRB_00113794	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00007803	Specialty Medication Adherence Rates in Patients with Rheumatoid Arthritis Across Health-System Specialty Pharmacies	IRB_00126221	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00007994	Laboratory Testing of the AAV5 Total Antibody Assay for use in determining eligibility for the Phase 3 Clinical Study BMN 270-301	IRB_00105443	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00008043	20140106 (formerly CFZ008): Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia	IRB_00078377	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00008053	Ohio State University OSU-18311 >> A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax (phase 2)	IRB_00125799	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00008120	Parker Institute PIC0014 >> A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination with Anti-PD-1 Therapy in Adult Patients wi	IRB_00124783	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Seres Therapeutics	remuneration	\$40,000-59,999
ICI_00008124	Comparing effectiveness, complications, and cost for second-line treatments of immune thrombocytopenia (ITP) in a cohort of U.S. Veterans	IRB_00116035	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00008153	Eli Lilly I3Y-MC-JPCM Clinical Protocol>>A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer	IRB_00117018	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00008153	Eli Lilly I3Y-MC-JPCM Clinical Protocol>>A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer	IRB_00117018	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00008156	NRG-LU003 (CIRB) >> A Biomarker-Driven Protocol for Previously Treated NSCLC ALK Positive Patients: The NCI-NRG-ALK Protocol	IRB_00126342	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00008167	Evaluation of Infections among Patients Receiving Ibrutinib	IRB_00126928	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00008183	Amgen 20150161>>A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia	IRB_00105925	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00008192	RTOG 1016: Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer	IRB_00051444	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00008244	Novartis CVAY736Y2102 >> Phase Ib open-label study of VAY736 and ibrutinib in pat	IRB_00126007	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000

Reference	Research Project Title	IRB	Name of Conflicted	Business Entity	Nature of Financial Interest	Approximate Dollar Value
ICI_00008265	CR_9/23/2019 9:57 AM - Laboratory Testing of the AAV5 Total Antibody Assay for us	IRB_00106161	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00008275	Janssen 56021927PCR2032>>An Open-label, Multicenter, Phase 1b Study of JNJ-637	IRB_00126545	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00008316	CR_10/14/2019 1:30 PM - A Single-Center, Single-Blind, Placebo-Controlled Study to	IRB_00110974	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00008323	Celgene CC-220-MM-001 >> A Phase 1b/2a Multicenter, Open-Label, Dose Escalatio	IRB_00125677	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Johnson & Johnson Amgen	remuneration and a deferred stock award equity	greater than \$100,000 greater than \$100,000
ICI_00008433	CR_10/22/2019 11:51 AM - AALL1331, Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B Lymphoblastic Leukemia (B-ALL)	IRB_00079750	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00008435	307-902: A Prospective Study of Phenylketonuria (PKU)	IRB_00126507	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00008570	Laboratory monitoring for denosumab in solid tumor patients with bone metastases at an academic medical center	IRB_00127176	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00008659	CR_11/1/2019 2:09 PM - Amgen AMG510 20170543 >> A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and	IRB_00115397	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00008718	A Blanket BioMarin Study to Observe Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)	IRB_00127920	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00008732	CR_11/13/2019 8:31 AM - Validation of Methods to Identify Hospitalizations for ESRD Patients Requiring RBC Transfusion: Patterns and Outcomes of Hyperkalemia Management among U.S. Veterans Affairs Patients (POHM-VA)	IRB_00076613	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00008884	CR_11/20/2019 12:08 PM - Severe Chronic Neutropenia International Registry	IRB_00030240	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00008999	Mersana MER-XMT-1536-1>>A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b	IRB_00128214	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Mersana	remuneration	\$40,000-59,999
ICI_00009012	AAV5 Antibody Testing Services for BioMarin's Clinical Study Protocol BMN 307-201	IRB_00128276	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00009028	ECOG-ACRIN EAA173 (NCI CIRB)>>Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)	IRB_00128092	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00009162	CR_12/16/2019 3:42 PM - PCSK9 Inhibitor Initiation among Medicare Beneficiaries and Veterans: A case-crossover study	IRB_00115091	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00009207	CR_11/22/2019 3:30 PM - DF HCC 16-443>>Individualized Screening trial of Innovative Glioblastoma Therapy (INSIGHT)	IRB_00099040	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00009238	A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis	IRB_00127487	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00009404	CR_12/31/2019 10:08 AM - AbbVie M15-538>> A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma	IRB_00096767	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00009450	CR_1/7/2020 1:31 PM - I6T-MC-AMAH - A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis - OASIS-3	IRB_00116064	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000

Reference	Research Project Title	IRB	Name of Conflicted	Business Entity	Nature of Financial Interest	Approximate Dollar Value
ICI_00009451	CR_12/9/2019 1:42 PM - 11F-MC-RHCR – A 24-Week Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis	IRB_00115934	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00009474	CR_1/13/2020 1:38 PM - Amgen 20110266>>A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IV M1a Melanoma	IRB_00076872	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00009493	CR_1/3/2020 11:37 AM - Amgen 20110264>>A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Melanoma	IRB_00059240	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00009516	CR_1/2/2020 11:52 AM - AAV5 Antibody Testing Services for BioMarin's Phase 1/2 Clinical Study	IRB_00119210	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00009517	CR_1/2/2020 11:51 AM - Laboratory Testing of the AAV5 Total Antibody Assay for use in determining AAS Status of Participants in the Clinical Studies BMN 270-901 and BMN 270-902	IRB_00107924	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00009657	STAGGER: A Randomized, Phase II Study of Staggered, Chemo-Immunotherapy with Durvalumab, MEDI4736 Pemetrexed and Carboplatin (PC) for Metastatic Non-Squamous NSCLC	IRB_00127115	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00009666	Clinical disease manifestation associated with anti-TNF non-response in Juvenile Spondyloarthritis	IRB_00128425	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00009843	CR_2/7/2020 4:31 PM - LOXO-RET-17001>> A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)	IRB_00110969	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00009983	SWOG S1803 (CIRB) >> Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Du	IRB_00130745	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00010062	CR_2/26/2020 10:28 PM - Clinical Surveillance Program for Patients with Mucopolysaccharidosis Type VI	IRB_00034057	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00010091	Project RACR: Promoting Resilience, Adjustment, and Community Reintegration after Spinal Cord Injury (SCI)	IRB_00130225	Ruth Watkins, President of the University of Utah the University of Utah	Craig H. Neilsen Foundation Craig H. Neilsen Foundation	remuneration gift to the institution	\$5,000-9,999 greater than \$100,000
ICI_00010135	CR_3/2/2020 1:42 PM - Amgen 20120139 Registry>>A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVex Sponsored Clinical Trials	IRB_00077641	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00010219	Janssen JNJ-68284528MMY3002 >> A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PvD) or Daratumumab, Pomalidomide and Dexametha	IRB_00130881	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00010285	CR_3/16/2020 10:29 AM - Amgen 20170122>> A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma	IRB_00119834	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00010288	CR_3/11/2020 2:23 PM - Eli Lilly I5B-MC-JGDP>>A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer	IRB_00100890	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00010380	CR_3/23/2020 10:58 AM - Preterm Epo Neuroprotection Trial (PENUT Trial)	IRB_00063749	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000

Reference	Research Project Title	IRB	Name of Conflicted	Business Entity	Nature of Financial Interest	Approximate Dollar Value
ICI_00010388	CR_3/24/2020 2:10 PM - Emory/Winship 4398-18 >> PD1 Blockade and Oncolytic Virus in Relapsed Multiple Myeloma	IRB_00121001	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00010576	CR_4/7/2020 12:50 PM - Amgen 20110265 >> A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable, Stage IIIB to IVM1c Melanoma (MASTERKEY-265)	IRB_00076066	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00010582	Treatment patterns and outcomes of marginal zone lymphoma patients in the USA – A Real-world analysis	IRB_00132382	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00010647	Identifying care pathways to PCSK9 inhibitor initiation among Veterans after myocardial infarction in the PCSK9 inhibitor era.	IRB_00132601	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00010706	DRM06-AD05 - A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis	IRB_00130127	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00010777	CR_4/20/2020 10:07 AM - PKUDOS – PKU Demographics, Outcomes, and Safety Registry PKU MOMS- Subregistry for pregnant PKU moms	IRB_00031175	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00010926	CR_5/4/2020 10:47 AM - Central Pathology Review and Biology Studies for COG AALL1731 Trial	IRB_00122191	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00010998	CR_5/6/2020 10:06 AM - Mild Encephalopathy in the Neonate treated with Darbepoetin (MEND)	IRB_00102053	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00011033	CR_5/12/2020 9:38 AM - RTOG 0617: A Randomized Phase III Comparison of Standard-Dose (60 Gy) versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/	IRB_00029859	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00011092	SupportGroove: an mHealth app to support persons with spinal cord injury and caregivers during COVID-19	IRB_00133430	Ruth Watkins, President of the University of Utah the University of Utah	Craig H. Neilsen Foundation Craig H. Neilsen Foundation	remuneration gift to the institution	\$5,000-9,999 greater than \$100,000
ICI_00011172	Amgen 20190135 >> A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation	IRB_00132465	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00011180	CR_5/18/2020 12:40 PM - 20140315: Phase 3, Randomized, Open-label, Controlled, Multiple-Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 days to <18 Years of age With Secondary Hyperparathyroidism	IRB_00116991	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00011199	CR_5/25/2020 9:22 AM - Reducing Intracranial atherosclerosis with Repatha (RISER)	IRB_00121763	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00011210	CR_5/26/2020 7:39 AM - Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants	IRB_00101392	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00011394	A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults	IRB_00134027	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00011411	CR_6/11/2020 11:32 AM - Exploring Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus	IRB_00086646	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00011438	CR_5/15/2020 12:03 PM - Sinonasal Tissue Repository	IRB_00074325	the University of Utah	Glycomira Therapeutics	equity	value cannot be readily determined
ICI_00011464	CR_6/8/2020 8:41 AM - NCI 9603>>Pilot Trial Evaluating the Combination of Reolysin and Carfilzomib in Multiple Myeloma	IRB_00103695	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00011477	CR_6/16/2020 2:51 PM - High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL): A randomized, placebo-controlled, double-masked 500-subject clinical trial of erythropoietin for the treatment of neonatal hypoxic-ischemic encephalopathy (HIE)	IRB_00093313	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000

Reference	Research Project Title	IRB	Name of Conflicted	Business Entity	Nature of Financial Interest	Approximate Dollar Value
ICI_00011503	CR_6/19/2020 9:47 AM - An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects with Breast Cancer	IRB_00103657	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00011569	CR_6/24/2020 12:59 PM - RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer	IRB_00038978	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00011584	GSK DREAMM7 >> A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexam	IRB_00132175	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00011678	AAV5 Antibody Testing Services for BioMarin's Clinical Study Protocol BMN 270-205	IRB_00134497	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00011881	A Prospective, Observational Study Evaluating Seroprevalence and Rate of Seroconversion of Antibodies against Adeno-associated Virus (AAV) Serotypes and Exploratory Vectors in Subjects with Hemophilia A in the United States	IRB_00135341	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00011890	CR_6/22/2020 9:26 AM - AAV5 Antibody Testing Services for BioMarin's Clinical Study Protocol BMN 270-203	IRB_00124471	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00012106	Janssen 73841937NSC1001>>An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody	IRB_00135665	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00012150	Eli Lilly I3Y-MC-JPCY>>CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration- Resistant Prostate Cancer Patients Previously Treated with a Novel Hormonal Agent and Taxane-based Chemotherapy	IRB_00135495	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00012197	The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)	IRB_00129943	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00012208	ACTIV-3: A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19 Short Title: Therapeutics for Inpatients with COVID-19 (TICO)	IRB_00135753	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00012277	JASPER JSP-CP-003 >> A Phase 1 Study to Evaluate the Safety and Tolerability of JSP191 in Combination with a Reduced Intensity Conditioning Regimen of Low Dose Radiation and Fludarabine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leu	IRB_00135115	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00012406	GOG Foundation GOG-3039>>A Phase II Study of Abemaciclib in Combination with Letrozole in Advanced, Recurrent or Metastatic Endometrioid Endometrial Cancer	IRB_00136414	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00012667	AAV5 Antibody Testing Services for BioMarin's Clinical Study Protocol BMN 270-303	IRB_00127458	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00012736	Alloimmunization Rates in Patients with Multiple Myeloma Treated with Daratumumab	IRB_00134965	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00012841	Heredigene: Population Study: Heredigene Pediatric	IRB_00137559	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00012900	AstraZeneca D910LC00001 (MeRmaiD1)>> A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (IRB_00137023	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00012935	AAV5 Antibody Testing Services for BioMarin's Clinical Study Protocol BMN 270-203	IRB_00137774	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00013066	cvMOBIUS: The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (EHR Sub-Study)	IRB_00138145	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00013212	Outcomes and toxicities of off-label uses of CDK 4/6 inhibitors in solid and hematologic malignancies	IRB_00138365	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000

Reference	Research Project Title	IRB	Name of Conflicted	Business Entity	Nature of Financial Interest	Approximate Dollar Value
ICI_00013243	Novel Approaches for Improving Vascular Function in Veterans with HFpEF	IRB_00138675	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00013283	Seattle Genetics SGNTUC-022 >> MOUNTAINEER-02: A Randomized, Double-Blind, Placebo-Controlled, Active Comparator Phase II/III Study Of Tucatinib In Combination With Trastuzumab, Ramucirumab, And Paclitaxel In Subjects With Previously Treated, Locally-Adv	IRB_00138427	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00013379	ETCTN 10076 (CIRB)>>A Phase 1 Dose-Escalation And Exploratory Dose Expansion Study Of KRT-232 (AMG 232) In Combination with Carfilzomib, Lenalidomide, And Dexamethasone In Relapsed And/Or Refractory Myeloma	IRB_00138747	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00013380	CR_11/9/2020 9:36 AM - Exploration of Simulation, Controls, and Real-World Experiences for Spinal Cord Injury Sport Experiences	IRB_00118152	Ruth Watkins, President of the University of Utah the University of Utah	Craig H. Neilsen Foundation Craig H. Neilsen Foundation	remuneration gift to the institution	\$5,000-9,999 greater than \$100,000
ICI_00013450	ECOG-ACRIN EAA181 (CIRB): Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma Not Intended For Early Autologous Transplantation	IRB_00139305	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00013464	A retrospective study on the association between erythropoietin or darbepoietin administration and the rate of retinal vascularization in premature infants.	IRB_00138629	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00013643	DRM06-AD07 - A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis	IRB_00138159	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00013653	Janssen 67652000PCR3002>>A Phase III Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germl	IRB_00138516	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00013678	CIRB AALL1821 A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >=1 to <31 Years Old with First Relapse	IRB_00139680	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00013779	CR_1/5/2021 9:51 AM - AEWS1221: Randomized Phase III Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma	IRB_00079080	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00013877	Determining the effectiveness of the Hope4Utah program: A school-based suicide intervention	IRB_00139566	the University of Utah	Wheeler Foundation Fund	gift to the institution	greater than \$100,000
ICI_00013926	A Longitudinal Study of Hyperphenylalaninemia	IRB_00138750	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00014069	SupportGroove: a novel mhealth intervention for couples coping with spinal cord injury	IRB_00140826	Ruth Watkins, President of the University of Utah the University of Utah	Craig H. Neilsen Foundation Craig H. Neilsen Foundation	remuneration gift to the institution	\$5,000-9,999 greater than \$100,000
ICI_00014448	Treatment Outcomes of Diffuse Large B-Cell Lymphoma with Secondary Central Nervous System Involvement	IRB_00141932	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00014499	Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients with CLL/SLL	IRB_00141704	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00014556	ETCTN 10030 CIRB >> Phase I Study of Blinatumomab in Combination with Checkpoint Inhibitor	IRB_00141233	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00014715	CR_4/9/2021 12:49 PM - Fox Chase Cancer Center TH-138 >> Phase II randomized trial	IRB_00130928	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000

Reference	Research Project Title	IRB	Name of Conflicted	Business Entity	Nature of Financial Interest	Approximate Dollar Value
ICI_00014727	CR_4/1/2021 10:41 AM - Dyslipidemia of Obesity Intervention in Teens - DO IT! Trial	IRB_00101216	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00014799	Sensory Amplifications as Biomarkers of Migraine Progression	IRB_00135109	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00014884	KRAS Mutant: A Single Arm Phase II study of Cetuximab in Third Line for Mutant APC	IRB_00141689	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00015311	BESTMED: Observational Evaluation of Second-Line Therapy Medications in Diabetes	IRB_00144499	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000
ICI_00009415	A Phase I/II Clinical Trial to Determine Safety and Feasibility of Using an Acellular Amniotic Fluid Application to Expedite Healing in Chronic Wounds (pAF for Chronic Wounds)	IRB_00128708	the Department of Internal Medicine and University of Utah	Eliska	equity	value cannot be readily determined
ICI_00012891	A Phase I/II Double-Blinded Randomized Prospective Study of Sterile Amniotic Fluid Filtrate Epidural Injection for the treatment of Lumbosacral Radicular Pain due to Spinal Stenosis: The SAFE Trial (Improving Safety and Outcomes in the Treatment of Pain and Disability Related to Spinal Stenosis).	IRB_00131761	the Department of Internal Medicine and University of Utah	Eliska	equity	value cannot be readily determined
ICI_00011303	A Phase I/II Randomized Double-Blinded Placebo-Controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Sterile Filtered Amniotic Fluid as a Treatment for COVID-19 Patients	IRB_00132922	the Department of Internal Medicine and University of Utah	Eliska	equity	value cannot be readily determined
ICI_00014122	A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY FOR THE TREATMENT OF OCULAR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) WITH PROCESSED AMNIOTIC FLUID (pAF) DROPS	IRB_00103515	The Department of Internal Medicine and The University of Utah	Eliksa	equity	value cannot be readily determined
ICI_00013898	A Phase I/II Randomized, Double-Masked, Placebo-Controlled Study for determining the safety of processed Amniotic Fluid (pAF) Drops after Photorefractive Keratectomy	IRB_00099569	The Department of Internal Medicine and The University of Utah	Eliksa	equity	value cannot be readily determined
ICI_00013650	Standardized Wound Care and Monitoring for Systemic Sclerosis-related Digital Ulcer	IRB_00127293	The Department of Internal Medicine and The University of Utah	Eliksa	equity	value cannot be readily determined
ICI_00012917	A Phase I/II Randomized Double-Blinded Standard of Care (Corticosteroid) vs. Sterile Amniotic Fluid for Osteoarthritis	IRB_00128491	The Department of Internal Medicine and The University of Utah	Eliksa	equity	value cannot be readily determined
ICI_00011960	Human Amniotic Membrane for Pericardium Substitute in Cardiac Surgery Patients	IRB_00113483	The Department of Internal Medicine and The University of Utah	Eliksa	equity	value cannot be readily determined
ICI_00011874	Use of amniotic membrane for the treatment of idiopathic tracheal stenosis.	IRB_00118330	The Department of Internal Medicine and The University of Utah	Eliksa	equity	value cannot be readily determined
ICI_00015754	Mersana Therapeutics, Inc. MER-XMT-1536-2 >> An Open-Label, Multicenter, Dose Escalation and Expansion Modular, Umbrella Master Study of Upifitamab Rilsodotin in Combination with Other Agent(s) in Participants with High-Grade Serous Ovarian Cancer (UPGRADE)	IRB_00145128	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Mersana Therapeutics	Remuneration	\$40,000-59,999
ICI_00015735	Identifying care pathways to PCSK9 inhibitor initiation among Veterans after myocardial infarction in the PCSK9 inhibitor era	IRB_00145802	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00015560	Epizyme EZH-302 >> A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma	IRB_00134567	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00015736	University of Miami ADVANCE >> Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)	IRB_00144612	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine Mary Beckerle, CEO and Director at Huntsman Cancer Institute, reports a significant financial interest with Johnson & Johnson	Amgen Johnson & Johnson	equity remuneration and a deferred stock award	greater than \$100,000 greater than \$100,000
ICI_00015792	Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects with Chronic Immune Thrombocytopenia (ITP) after Switching to Avatrombopag from Eltrombopag or Romiplostim	IRB_00143504	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00015958	Effect of second-line antidiabetic drugs add-on to metformin on cardiovascular events in patients with type 2 diabetes mellitus	IRB_00146383	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Eli Lilly and Company	equity	greater than \$100,000

Reference	Research Project Title	IRB	Name of Conflicted	Business Entity	Nature of Financial Interest	Approximate Dollar Value
ICI_00016178	A Phase I/II Randomized Double-Blinded Placebo-Controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Sterile Filtered Amniotic Fluid as a Treatment for COVID-19 Patients	IRB_00132922	The Department of Internal Medicine and The University of Utah	Eliksa	equity	value cannot be readily determined
ICI_00016280	NCI CIRB: AGCT1532- Phase 3 Accelerated BEP Trial:A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours	IRB_00119849	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00016389	Amgen Inc. 20180101 (SIRB) >> Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-Life Extended Bispecific T-Cell Engager AMG 160 in Subjects With Metastatic Castration-Resistant Prostate Cancer	IRB_00145729	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00015480	T2018-001 A retrospective cohort study of response and survival in pediatric patients with relapsed and refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy) treated with contemporary salvage therapy.	IRB_00142851	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00016411	CR_9/30/2021 11:47 AM - SWOG S1826 >> A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma	IRB_00126350	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00016451	CR_10/5/2021 3:44 PM - CIRB: AALL1731, A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment	IRB_00124257	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00016760	CR_10/19/2021 12:48 PM - RTOG 0839>>Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer	IRB_00060850	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00016768	CR_10/26/2021 9:02 AM - SWOG S1607 (NCI CIRB) >> A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy	IRB_00117626	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00016823	CR_10/22/2021 12:30 PM - Alliance/ECOG-ACRIN E1910 (CIRB)>>A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults	IRB_00084699	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00016863	Amgen, Inc. 20200439 >> Phase IB Study Evaluating the Safety and Efficacy of AMG 757 in Combination with AMG 404 in Subjects with Small Cell Lung Cancer (SCLC)	IRB_00146758	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	Amgen	equity	greater than \$100,000
ICI_00017045	CR_11/11/2021 11:31 AM - NRG GU006 (NCI CIRB)>> A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer	IRB_00118912	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000
ICI_00017071	AAV5 Antibody Testing Services for the BioMarin Clinical Study- A Phase 1/2, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of BMN 331, an Adeno-Associated Virus (AAV) Vector-Mediated Gene Transfer of Human SERPING1	IRB_00149030	Dr. Willard Dere, Associate Vice President for Research and Vice Dean for Research in the School of Medicine	BioMarin	remuneration	greater than \$100,000
ICI_00016070	Janssen 75229414MPC1001 >> A Phase 1, Dose Escalation Study of JNJ-75229414, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer	IRB_00146419	Dr. Mary Beckerle, CEO and Director at Huntsman Cancer Institute	Johnson & Johnson	remuneration and a deferred stock award	greater than \$100,000